Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

MLA

Arbour, Kathryn C., et al. “Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 36, no. 28, Oct. 2018, pp. 2872–78. EBSCOhost, https://doi.org/10.1200/JCO.2018.79.0006.

APA

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., Sabari, J. K., Caramella, C., Plodkowski, A. J., Halpenny, D., Chaft, J. E., Planchard, D., Riely, G. J., Besse, B., & Hellmann, M. D. (2018). Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 36(28), 2872–2878. https://doi.org/10.1200/JCO.2018.79.0006

Chicago

Arbour, Kathryn C, Laura Mezquita, Niamh Long, Hira Rizvi, Edouard Auclin, Andy Ni, Gala Martínez-Bernal, et al. 2018. “Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36 (28): 2872–78. doi:10.1200/JCO.2018.79.0006.